Literature DB >> 21677651

Persistent increase in hypothalamic arginine vasopressin gene expression during protracted withdrawal from chronic escalating-dose cocaine in rodents.

Yan Zhou1, Yoav Litvin, Anna Paola Piras, Donald W Pfaff, Mary Jeanne Kreek.   

Abstract

Arginine vasopressin (AVP) from the paraventricular nucleus (PVN) of hypothalamus has important roles in regulation of the hypothalamic-pituitary-adrenal (HPA) axis and stress-related behaviors during chronic stress. It is unknown, however, whether AVP in the PVN is involved in the modulation of HPA activity after chronic cocaine exposure. Here, we examined the gene expression alterations of AVP in the hypothalamus, and V1b receptor and pro-opiomelanocortin (POMC) in the anterior pituitary, as well as HPA hormonal changes, in Fischer rats after chronic cocaine and withdrawal, using two different chronic (14-day) 'binge' pattern administration regimens: steady-dose cocaine (SDC, 45 mg/kg/day) and escalating-dose cocaine (EDC, 45 up to 90 mg/kg/day). There was a significant (7-fold) plasma adrenocorticotropic hormone (ACTH) elevation after chronic EDC (but not SDC), coupled with increased V1b and POMC mRNA levels in the anterior pituitary. From acute (1-day) to protracted (14-day) withdrawal from chronic EDC (but not from SDC), we found persistent elevations of both plasma ACTH and corticosterone levels and AVP mRNA levels in the PVN. Selective V1b antagonist SSR149415 (5 mg/kg) attenuated acute withdrawal-induced HPA activation after EDC. To study potential roles of endogenous opioids in modulating the AVP gene, we administered naloxone (1 mg/kg); we found that opioid receptor antagonism increased AVP mRNA levels in cocaine-naive rats, but not in cocaine-withdrawn rats, suggesting less tonic opioid inhibition of PVN AVP neurons after chronic EDC. To assess the effects of cocaine withdrawal on sub-populations of PVN AVP neurons, we utilized AVP-enhanced green fluorescent protein (EGFP) promoter transgenic mice and found that acute withdrawal following chronic EDC increased the number of AVP-EGFP neurons in the parvocellular PVN (pPVN). These results suggest that during protracted withdrawal, enhanced pPVN AVP gene expression is associated with persistent elevations of basal HPA activity; a hyposensitivity of PVN AVP gene expression to naloxone is indicative of reduced opioidergic tone. Our studies indicate that the AVP and its V1b receptor system may be a potential therapeutic target for treating anxiety and depressive symptoms associated with cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677651      PMCID: PMC3158323          DOI: 10.1038/npp.2011.97

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  54 in total

1.  Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone.

Authors:  R L Moldow; A J Fischman
Journal:  Peptides       Date:  1987 Sep-Oct       Impact factor: 3.750

2.  Chronic cocaine administration sensitizes behavioral but not neuroendocrine responses.

Authors:  B Borowsky; C M Kuhn
Journal:  Brain Res       Date:  1991-03-15       Impact factor: 3.252

3.  Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo.

Authors:  C Rivier; W Vale
Journal:  Endocrinology       Date:  1983-09       Impact factor: 4.736

4.  Stimulatory effect of cocaine on ACTH secretion: role of the hypothalamus.

Authors:  C Rivier; S Lee
Journal:  Mol Cell Neurosci       Date:  1994-04       Impact factor: 4.314

5.  Diurnal variations in plasma ACTH, cortisol and beta-endorphin levels in cocaine addicts.

Authors:  P P Vescovi; V Coiro; R Volpi; M Passeri
Journal:  Horm Res       Date:  1992

6.  DHEAS and POMS measures identify cocaine dependence treatment outcome.

Authors:  J N Wilkins; M D Majewska; W Van Gorp; S H Li; C Hinken; D Plotkin; D Setoda
Journal:  Psychoneuroendocrinology       Date:  2005-01       Impact factor: 4.905

7.  Neuroendocrine responses to cocaine do not exhibit sensitization following repeated cocaine exposure.

Authors:  A D Levy; Q Li; M C Alvarez Sanz; P A Rittenhouse; J E Kerr; L D Van de Kar
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

Review 8.  Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age.

Authors:  F A Antoni
Journal:  Front Neuroendocrinol       Date:  1993-04       Impact factor: 8.606

9.  Foot shock stress-induced release of vasopressin in adenohypophysectomized and hypophysectomized rats.

Authors:  W Knepel; R Przewlocki; D Nutto; A Herz
Journal:  Endocrinology       Date:  1985-07       Impact factor: 4.736

10.  Immunohistochemical analysis of magnocellular elements in rat hypothalamus: distribution and numbers of cells containing neurophysin, oxytocin, and vasopressin.

Authors:  C H Rhodes; J I Morrell; D W Pfaff
Journal:  J Comp Neurol       Date:  1981-05-01       Impact factor: 3.215

View more
  18 in total

Review 1.  Effects of cocaine on the hypothalamic-pituitary-adrenal axis.

Authors:  L Manetti; F Cavagnini; E Martino; A Ambrogio
Journal:  J Endocrinol Invest       Date:  2014-05-23       Impact factor: 4.256

2.  Corticotropin-releasing factor receptor 2-deficiency eliminates social behaviour deficits and vulnerability induced by cocaine.

Authors:  Nadège Morisot; Romain Monier; Catherine Le Moine; Mark J Millan; Angelo Contarino
Journal:  Br J Pharmacol       Date:  2018-03-13       Impact factor: 8.739

3.  Functions of arginine vasopressin and its receptors: importance of human molecular genetics studies in bidirectional translational research.

Authors:  Mary Jeanne Kreek; Yan Zhou; Orna Levran
Journal:  Biol Psychiatry       Date:  2011-09-15       Impact factor: 13.382

Review 4.  Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.

Authors:  Mary Jeanne Kreek; Orna Levran; Brian Reed; Stefan D Schlussman; Yan Zhou; Eduardo R Butelman
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 5.  Utility of genetically modified mice for understanding the neurobiology of substance use disorders.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Hum Genet       Date:  2011-12-22       Impact factor: 4.132

6.  Individual differences in gene expression of vasopressin, D2 receptor, POMC and orexin: vulnerability to relapse to heroin-seeking in rats.

Authors:  Yan Zhou; Francesco Leri; Erin Cummins; Mary Jeanne Kreek
Journal:  Physiol Behav       Date:  2014-11-09

7.  Chronic treatment with the vasopressin 1b receptor antagonist SSR149415 prevents the dysphoria associated with nicotine withdrawal in rats.

Authors:  Xiaoli Qi; Lidia Guzhva; Yue Ji; Adriaan W Bruijnzeel
Journal:  Behav Brain Res       Date:  2015-06-22       Impact factor: 3.332

8.  Assessment of the impact of pattern of cocaine dosing schedule during conditioning and reconditioning on magnitude of cocaine CPP, extinction, and reinstatement.

Authors:  Kelly L Conrad; Katherine M Louderback; Elana J Milano; Danny G Winder
Journal:  Psychopharmacology (Berl)       Date:  2012-12-28       Impact factor: 4.530

Review 9.  Stress, sex, and addiction: potential roles of corticotropin-releasing factor, oxytocin, and arginine-vasopressin.

Authors:  Verónica Bisagno; Jean Lud Cadet
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

Review 10.  Medications for substance use disorders (SUD): emerging approaches.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Expert Opin Emerg Drugs       Date:  2017-10-30       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.